Cardiovascular Outcomes with New Diabetes Medications
Jane E Reusch, MD
Denver VAMC
Diabetes impacts more than 38 million people in the US and more than half a billion people globally. It takes its toll on individuals living with diabetes through microvascular and macrovascular complications. We have extraordinary data to drive goal directed medical therapy to decrease cardiovascular risk that is ineffectively executed in the clinical setting. We will discuss a series of cases stressing the need for comprehensive cardiovascular risk factor management and emphasize the role for the newer agents, SGLT-2 inhibitors and GLP-1 receptor agonists, for further mitigating cardiovascular risk and optimizing glycemic control.